Vaccine Info

HBA120 Hepatitis B Vaccine

Authored by
Staff
Last reviewed
January 24, 2021
Fact checked by
Robert Carlson, MD

HBA120 Hepatitis B Vaccine Description

HBAI20 vaccine candidate consists of a standard HBV vaccine to which the AI20 adjuvant is added.

The adjuvant can give an additional stimulus to the immune system and provide sufficient protection against HBV for the non-responders.

CyTuVax has successfully finished Phase 1 clinical study of HBAI20, a specialized vaccine for people who were initially non-responders to standard hepatitis B vaccination. To read more about this study, see the publication of O. Koc et al. (2018). The phase 1 clinical trial showed that the HBAI20 vaccine was well tolerated among study participants and induced protective anti-hepatitis B-antibody titers in 9 out of 10 participants who were initially non-responders to standard hepatitis B vaccines.

CyTuVax is currently investigating, in a phase 2 clinical trial, the efficacy of the HBAI20 vaccine to induce seroprotection and compare the safety of the HBAI vaccine with the standard hepatitis B vaccination.

HBA120 Hepatitis B Vaccine Indication

The HBA120 vaccine candidate is indicated for HBV non-responders.

Also, the HBAI20 gives faster protection, offering fewer vaccinations in the future.

HBA120 Hepatitis B Vaccine Clinical Trials

Clinical Trial NCT03415672: Hepatitis B Vaccine for Non-responders. Last Update Posted: January 31, 2019.

In this Phase 2 trial, the investigators study the efficacy of the HBAI20 vaccine to induce seroprotection in registered non-responders (adults who were previously vaccinated with the HBVaxPro-10μg but did not achieve seroprotection). The study will further assess the safety of the HBAI20 vaccine in comparison with HBVaxPro-10μg.